Lyme disease

Active Ingredient: Cefuroxime

Indication for Cefuroxime

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

For this indication, competent medicine agencies globally authorize below treatments:

1000 mg in 2 divided doses daily

Route of admnistration

Oral

Defined daily dose

1,000 - 1,000 mg

Dosage regimen

From 500 To 500 mg 2 time(s) per day every day

Detailed description

500 mg twice daily.

Dosage considerations

It should be taken after food for optimum absorption.

Active ingredient

Cefuroxime

Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

Read more about Cefuroxime

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.